Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endologix rebuffs takeover bid

This article was originally published in The Gray Sheet

Executive Summary

Maker of Powerlink endoluminal stent grafts for abdominal aortic aneurysms rejects as inadequate an unsolicited takeover bid from hedge fund Elliott Associates. The Oct. 13 offer was worth about $98 million, or $2.25 per share. "We believe that volatility in the capital markets has negatively affected micro-cap companies like Endologix, and we expect the situation to improve in the future," CEO John McDermott explains in a Nov. 13 statement (1"The Gray Sheet" Oct. 20, 2008, In Brief)
Advertisement

Related Content

Big week for Endologix
Advertisement
UsernamePublicRestriction

Register

MT026796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel